Jefferies survey 'extremely bullish' for Kite's Axi-celJefferies analyst Biren Amin says his firm's first proprietary survey on the non-Hodgkin lymphoma landscape proved "extremely bullish" for Kite Pharma's Axi-cel in 2018 and 2019. Respondents expect 30% and 40% of second-line patients to be treated with Axi-cel in the two years, Amin tells investors in a research note. The analyst believes the survey supports his above-consensus estimates. He keeps a Buy rating on Kite Pharma with a $101 price target. |